Adrian Newman-Tancredi

Neuropharmacology Consulting at NeuroAct Communication

Castres, Tarn, FR

Experienced public speaker and neuropharmacologist with proven expertise in study of antipsychotics, antidepressants and analgesics.

Description

Dr. Newman-Tancredi has over 20 years' experience of neuroscience research and drug discovery. Prior to joining Neurolixis, he was Director of Neurobiology and Project Manager at Pierre Fabre Laboratories where he led multi-disciplinary programs that successfully identified and characterized novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology research group at the Servier Research Institute where he was responsible for screening of NCEs and investigating signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella Â®), piribedil (Trivastal Â®), agomelatine (Valdoxan Â®) and befiradol (Ph. II). In addition, Dr. Newman-Tancredi managed projects that led to early development of compounds with novel profiles of action, including the antipsychotic candidate, F15063 and the antidepressant candidate, F15599.

Dr. Newman-Tancredi has extensive experience of team management, integrating medicinal chemistry, pharmacology, early ADMET and preclinical development, and building international collaborations with academic researchers. He has published over 130 research reports, co-authored patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology and as an independent neuropharmacology and drug discovery consultant (www.neuroact.com). Dr. Newman-Tancredi received his B.Sc. with honours in Biochemistry and his Ph.D. in neuropharmacology from the University of Kent at Canterbury, U.K. He is bi-national (anglo-italian) and tri-lingual (English, French, Italian).

Availability

Keynote, Moderator, Panelist, Workshop, Host/MC

Industry Expertise

Pharmaceuticals, Research, Mental Health Care

Topics

Antipsychotics, Neuropharmacology, Serotonin, Depression

Affiliations

NeuroAct Communication, Neurolixis Inc.

Sample Talks

Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined D2 and serotonin 5-HT1A activity.
This lecture presented the importance of serotonin 5-HT1A receptors as targets for the development of improved antipsychotics for the treatmenf of schizophrenia and related CNS disorders. The lecture focused on evidence from rodent models of psychosis, social withdrawal and cognitive deficits. Watch the Webcast of this lecture on YouTube: http://www.youtube.com/watch?v=vDc6QbwxUO8

Past Talks

The development of a novel generation of antipsychotics combining 5-HT1A agonism and D2 antagonism: rationale and new perspectives
9th International Meeting on the Early Phases of Mental Disorders

Antipsychotics in the post-patent cliff era: challenges for clinical and drug discovery research.
24th European College of Neuropsychopharmacology (ECNP) Congress

New mechanisms and novel drugs: how recent discoveries are opening perspectives for targeting serotonergic neurotransmission
Invited lecture: CERMEP Brain Imaging Centre

Pharmaceutical drug discovery - challenges and opportunities
Invited lecture: Neuropsychopharmacology Masters Degree students

Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined D2 and serotonin 5-HT1A activity.
23rd European College of Neuropsychopharmacology (ECNP) Congress

De la schizophrénie aux troubles de l'humeur: une brève histoire des antipsychotiques
10th Encéphale Congress of French Psychiatry

Psychopharmacology of monoamines
Association Française de Psychiatrie Biologique et de la Neuropsychopharmacologie (AFPBN)

Education

University of Kent at Canterbury
BSc Biochemistry

University of Kent at Canterbury
PhD Neuropharmacology

University of Kent at Canterbury
DSc Neuropharmacology

Please click here to view the full profile.

This profile was created by